药物性肝损伤与自身免疫性肝炎的鉴别诊断与治疗策略

卞兆连; 邵建国; 马雄

doi:10.3969/j.issn.1001-5256.2018.06.003

药物性肝损伤与自身免疫性肝炎的鉴别诊断与治疗策略

DOI: 10.3969/j.issn.1001-5256.2018.06.003

1. 南通市第三人民医院消化内科南通市肝病研究所
2. 上海交通大学医学院附属仁济医院消化科上海市消化疾病研究所

详细信息

中图分类号: R575
计量
- 文章访问数: 3066
- HTML全文浏览量: 36
- PDF下载量: 609
- 被引次数: 0
出版历程
- 收稿日期: 2018-03-31
- 出版日期: 2018-06-20

Differential diagnosis of drug-induced liver injury and autoimmune hepatitis and related therapeutic strategies

Nantong Institute of Liver Disease, Department of Gastroenterology and Hepatology, Nantong Third People's Hospital

摘要

摘要: 药物性肝损伤(DILI)与自身免疫性肝炎(AIH)的临床及组织学表现存在较多相似点,给临床医师的鉴别诊断带来困难。通过分别阐述DILI与AIH的关系、临床表现及组织学的异同点,帮助临床医师更好地鉴别DILI与AIH。总结了DILI与AIH治疗方案的选择,尤其着重介绍了在两者鉴别存在困难时,如何根据患者的病情选择不同的治疗策略,最终明确诊断。
- 药物性肝损伤 /
- 肝炎,自身免疫性 /
- 诊断,鉴别 /
- 治疗
Abstract: Drug-induced liver injury (DILI) and autoimmune hepatitis (AIH) have many similar clinical and histological manifestations, which brings difficulties to clinicians in differential diagnosis. This article elaborates on the association between DILI and AIH and their similarities and differences in clinical and histological manifestations, in order to help clinicians with the differential diagnosis of DILI and AIH.This article reviews the selection of therapeutic regimens for DILI and AIH and introduces how to select therapeutic strategies based on patient conditions and make a definite diagnosis when there are difficulties in differential diagnosis.
- drug-induced liver injury /
- hepatitis, autoimmune /
- diagnosis, differential /
- therapy

HTML全文

参考文献(26)

[1]KULLAK-UBLICK GA, ANDRADE RJ, MERZ M, et al.Druginduced liver injury:Recent advances in diagnosis and risk assessment[J].Gut, 2017, 66 (6) :1154-1164.

[2]WANG Q, YANG F, MIAO Q, et al.The clinical phenotypes of autoimmune hepatitis:A comprehensive review[J].J Autoimmun, 2016, 66:98-107.

[3]LUCENA MI, KAPLOWITZ N, HALLAL H, et al.Recurrent druginduced liver injury (DILI) with different drugs in the Spanish Registry:The dilemma of the relationship to autoimmune hepatitis[J].J Hepatol, 2011, 55 (4) :820-827.

[4]WEILER-NORMANN C, SCHRAMM C.Drug induced liver injury and its relationship to autoimmune hepatitis[J].J Hepatol, 2011, 55 (4) :747-749.

[5]PARIENTE EA, HAMOUD A, GOLDFAIN D, et al.Hepatitis caused by clometacin (Duperan) .Retrospective study of 30 cases.A model of autoimmune drug-induced hepatitis?[J].Gastroenterol Clin Biol, 1989, 13 (10) :769-774.

[6]European Association for the Study of the Liver.EASL Clinical Practice Guidelines:Autoimmune hepatitis[J].J Hepatol, 2015, 63 (4) :971-1004.

[7]CZAJA AJ.Drug-induced autoimmune-like hepatitis[J].Dig Dis Sci, 2011, 56 (4) :958-976.

[8]PERDICES EV, MEDINA-CALIZ I, HERNANDO S, et al.Hepatotoxicity associated with statin use:Analysis of the cases included in the Spanish Hepatotoxicity Registry[J].Rev Esp Enferm Dig, 2014, 106 (4) :246-254.

[9]GUZMAN G, KALLWITZ ER, WOJEWODA C, et al.Liver injury with features mimicking autoimmune hepatitis following the use of Black Cohosh[J].Case Rep Med, 2009, 2009:918156.

[10]EFE C, PURNAK T, OZASLAN E, et al.Drug-induced autoimmune hepatitis caused by anti-tumor necrosis factor alpha agents[J].Hepatology, 2010, 52 (6) :2246-2247.

[11]RODRIGUES S, LOPES S, MAGRO F, et al.Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy:A single center report of 8 cases[J].World J Gastroenterol, 2015, 28, 21 (24) :7584-7588.

[12]TERZIROLI BERETTA-PICCOLI B, MIELI-VERGANI G, BERTOLI R, et al.Atovaquone/proguanil-induced autoimmune-like hepatitis[J].Hepatol Commun, 2017, 1 (4) :293-298.

[13] de BOER YS, KOSINSKI AS, URBAN TJ, et al.Features of autoimmune hepatitis in patients with drug-induced liver injury[J].Clin Gastroenterol Hepatol, 2017, 15 (1) :103-112, e102.

[14]CHALASANI N, BONKOVSKY HL, FONTANA R, et al.Features and outcomes of 899 patients with drug-induced liver injury:The DILIN prospective study[J].Gastroenterology, 2015, 148 (7) :1340-1352, e1347.

[15]ANDRADE RJ, LUCENA MI, FERNANDEZ MC, et al.Drug-induced liver injury:An analysis of 461 incidences submitted to the Spanish registry over a 10-year period[J].Gastroenterology, 2005, 129 (2) :512-521.

[16]DEVARBHAVI H, RAJ S, ARADYA VH, et al.Drug-induced liver injury associated with Stevens-Johnson syndrome/toxic epidermal necrolysis:Patient characteristics, causes, and outcome in36 cases[J].Hepatology, 2016, 63 (3) :993-999.

[17]LIWINSKI T, SCHRAMM C.Autoimmune hepatitis-update on clinical management in 2017[J].Clin Res Hepatol Gastroenterol, 2017, 41 (6) :617-625.

[18]ZHANG WC, ZHAO FR, CHEN J, et al.Meta-analysis:Diagnostic accuracy of antinuclear antibodies, smooth muscle antibodies and antibodies to a soluble liver antigen/liver pancreas in autoimmune hepatitis[J].PLo S One, 2014, 9 (3) :e92267.

[19]SONTHALIA N, RATHI PM, JAIN SS, et al.Natural history and treatment outcomes of severe autoimmune hepatitis[J].J Clin Gastroenterol, 2017, 51 (6) :548-556.

[20]BALITZER D, SHAFIZADEH N, PETERS MG, et al.Autoimmune hepatitis:review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria[J].Mod Pathol, 2017, 30 (5) :773-783.

[21]KLEINER DE.Histopathological challenges in suspected drug-induced liver injury[J].Liver Int, 2018, 38 (2) :198-209.

[22]SUZUKI A, BRUNT EM, KLEINER DE, et al.The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis versus drug-induced liver injury[J].Hepatology, 2011, 54 (3) :931-939.

[23]DANAN G, TESCHKE R.Drug-induced liver injury:Why is the roussel uclaf causality assessment method (RUCAM) still used 25years after its launch?[J].Drug Saf, 2018.[Epub ahead of print].

[24]TESCHKE R, SCHULZE J, EICKHOFF A, et al.Drug induced liver injury:Can biomarkers assist RUCAM in causality assessment?[J].Int J Mol Sci, 2017, 18 (4) :e803.

[25]Drug-induced Liver Disease Study Group, Chinese Society of Hepatology, Chinese Medical Association.Guidelines for the management of drug-induced liver injury[J].J Clin Hepatol, 2015, 31 (11) :1752-1769. (in Chinese) 中华医学会肝病学分会药物性肝病学组.药物性肝损伤诊治指南[J].临床肝胆病杂志, 2015, 31 (11) :1752-1769.

[26]Chinese Society of Hepatology, Chinese Medical Association;Chinese Society of Gastroenterology, Chinese Medical Association;Chinese Society of Infectious Diseases, Chinese Medical Association.Consensus on the diagnosis and management of autoimmune hepatitis (2015) [J].J Clin Hepatol, 2016, 32 (1) :9-22. (in Chinese) 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会.自身免疫性肝炎诊断和治疗共识 (2015) [J].临床肝胆病杂志, 2016, 32 (1) :9-22.

施引文献

资源附件(0)

访问统计